Dolby Family Ventures

AI research assistant for biology.

Montara Therapeutics is a biotechnology company specializing in brain-specific pharmacology. It leverages human genetics and machine learning to identify and validate drug targets, aiming to enhance the safety and efficacy of treatments for neurological diseases.

Esper Satellite Imagery is a company focused on developing a constellation of hyperspectral imaging satellites equipped with in-house built imagers that cover over 100 spectral bands with a ground sampling distance of 1 meter. The company specializes in creating modular satellites capable of capturing detailed hyperspectral imagery to enhance agricultural practices and optimize mining operations. Their technology allows for precise measurements of various environmental factors, including water quality and plant health, which are essential for sustainable farming. Additionally, the satellites facilitate the identification of underground ore deposits, contributing to more efficient mining processes. Esper Satellite Imagery's capabilities also extend to monitoring the impacts of climate change, providing valuable environmental data to clients, and promoting resource efficiency for future generations.

NeuroBionics is developing advanced neural interface technology. Its key innovation lies in microscale, flexible bioelectronic fibers that combine electrical, chemical, and optical capabilities to sense and modulate biological environments. This enables researchers and medical professionals to enhance therapeutic interventions and develop novel treatments for neurological disorders.

Calicat is a clean-energy company developing a proprietary electrocatalyst discovery process for electrolyser. The company electrocatalyst discovery is an unprecedented, proprietary, end-to-end ultrahigh throughput AI and data-driven process focused on the discovery of new catalysts for the generation of clean hydrogen and fuel cell power production. The process prepares, characterizes, and quantifies the catalytic activity of millions of compositions per month and then closes the loop with big data analysis and AI to refine/guide the search.

Vandria is a biotechnology company focused on developing mitophagy inducers aimed at rejuvenating cells to combat aging and chronic diseases. By targeting the autophagy process, Vandria's products facilitate the elimination and recycling of damaged mitochondria, which is essential for maintaining proper mitochondrial function. This innovative approach seeks to help patients mitigate the effects of age-related disorders and improve overall health. Through its research and development efforts, Vandria aims to provide effective solutions for individuals facing the challenges associated with aging and chronic health conditions.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Montara Therapeutics is a biotechnology company specializing in brain-specific pharmacology. It leverages human genetics and machine learning to identify and validate drug targets, aiming to enhance the safety and efficacy of treatments for neurological diseases.

Progentos Therapeutics focuses on developing regenerative medicine therapies. Its primary approach involves stimulating the body's natural repair mechanisms to restore myelin in patients with multiple sclerosis, aiming to improve neurological function and enhance quality of life.

Esper Satellite Imagery is a company focused on developing a constellation of hyperspectral imaging satellites equipped with in-house built imagers that cover over 100 spectral bands with a ground sampling distance of 1 meter. The company specializes in creating modular satellites capable of capturing detailed hyperspectral imagery to enhance agricultural practices and optimize mining operations. Their technology allows for precise measurements of various environmental factors, including water quality and plant health, which are essential for sustainable farming. Additionally, the satellites facilitate the identification of underground ore deposits, contributing to more efficient mining processes. Esper Satellite Imagery's capabilities also extend to monitoring the impacts of climate change, providing valuable environmental data to clients, and promoting resource efficiency for future generations.

LeoLabs, Inc. designs and operates phased-array radar systems to track objects in low Earth orbit and provides space situational awareness data and services. It offers LeoLabs Collision Avoidance, a platform that automates satellite operations and enhances conjunction assessment and collision risk management, along with foundational LEO mapping data and services such as rapid orbit determination and ongoing orbit awareness. The company serves commercial satellite operators, government regulators and space agencies, and satellite management services markets. Founded in 2015 and headquartered in Menlo Park, California, LeoLabs provides a software platform with open API access that underpins space situational awareness and traffic safety services for safe and sustainable operations in space.

Motif Neurotech specializes in developing minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses, focusing initially on treatment-resistant depression. The company aims to restore hope and improve quality of life by providing personalized treatments that repair neural circuits.

Cognitive Space is a company that specializes in developing an artificial intelligence platform aimed at enhancing satellite constellation management. By leveraging machine intelligence, the platform facilitates mission management, collections planning, and communications link coordination for satellite operators. This innovative technology enables organizations to optimize their satellite capacity in response to dynamic market demands, thereby unlocking significant revenue and operational potential. Cognitive Space's solutions contribute to more effective monitoring of Earth, supporting economic, environmental, and national security initiatives within the rapidly evolving space industry.

Founded in 2015, Mojo Vision specializes in developing and commercializing advanced micro-LED display technology for various applications. The company is renowned for creating the world's smallest dynamic display for augmented reality smart contact lenses. Headquartered in Saratoga, California, Mojo Vision aims to disrupt the $160 billion display industry with its proprietary quantum-dot technology.

Sharrow Marine is a subsidiary of Sharrow Engineering, specializing in the research and development of high-performance propulsion technologies for both maritime and aeronautical applications. The company designs energy-efficient propellers that are custom-engineered to enhance performance across various sectors, including commercial marine shipping, aerospace, and recreational boating. Sharrow Marine's innovative solutions cater to a wide range of uses, ensuring clients can achieve improved efficiency in their propulsion systems.

Paradromics, Inc. is a company focused on developing advanced brain-machine interfaces aimed at transmitting data between the brain and external devices. Founded in 2015 and based in Austin, Texas, Paradromics manufactures implantable systems that facilitate neural data decoding, converting intricate neural recordings into data streams suitable for various neural prostheses. The company's technology is designed to enhance data transmission rates, providing high-volume, bidirectional data streaming capabilities. This innovation aims to assist individuals with neurodegenerative diseases and other neurological conditions by compensating for the loss of biological connectivity. In addition to its core products, Paradromics also develops applications to support its technology solutions.

Founded in 2018, Genemod specializes in developing inventory management software tailored for life scientists. Its platform integrates scientific tools with project management features, aiming to enhance collaboration and streamline daily operations within research labs.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Founded in 2015, Mojo Vision specializes in developing and commercializing advanced micro-LED display technology for various applications. The company is renowned for creating the world's smallest dynamic display for augmented reality smart contact lenses. Headquartered in Saratoga, California, Mojo Vision aims to disrupt the $160 billion display industry with its proprietary quantum-dot technology.

MooveAI is an automotive company that provides innovative solutions in end-to-end, predictive road intelligence analytics. Their first approach involves continuously collecting trillions of data points about road networks, including data about connected vehicles, road attributes, such as friction and traffic. The data is then integrated into our proprietary location analytics platform, where it is verified and analyzed. Finally, actionable insights are provided in the form of road risk scores that describe the relative safety of millions of individual road segments.

Switch Therapeutics is a biotechnology company founded in 2020 and based in San Francisco, California. The company focuses on revolutionizing RNA interference (RNAi) therapies by developing biomarker-gated genetic medicines. These innovative therapies utilize nucleic acid nanotechnology and RNAi science to target a variety of diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. Switch Therapeutics aims to provide healthcare providers with RNA molecules and therapies that can be activated selectively in specific cells, enhancing the precision of treatments for central nervous system diseases.

AccuKnox offers a zero-trust cloud security platform designed for cloud-native environments. The solution functions as a CNAPP and runtime security platform, protecting infrastructure and applications across public and private clouds, Kubernetes, virtual machines, bare metal, IoT Edge, and 5G. It emphasizes a DevSecOps-friendly and open-source approach while safeguarding the software development lifecycle. The platform isolates and protects container workloads using identity as a perimeter, monitors tainted data and networking, and applies system-level restrictions to defend applications, networks, and data against intrusions and misconfigurations. By providing comprehensive visibility and controls, AccuKnox helps organizations secure cloud-native workloads throughout the delivery pipeline.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Authentic Vision GmbH is a company specializing in anti-counterfeiting and authentication technologies aimed at safeguarding investments in product innovation, brand value, and reputation. Founded in 2012 and headquartered in Salzburg, Austria, with an additional office in Saratoga, California, the company offers a unique solution that includes a patented label technology combining QR code features with holographic security aspects. Its flagship product, the CheckifReal application, allows users to visually distinguish between authentic and counterfeit labels. Additionally, Authentic Vision provides services for customer communication, client label management, and business intelligence. The company holds multiple patents and collaborates closely with universities and leading security printing firms to remain at the forefront of advancements in brand protection and consumer engagement solutions.

Atomos Space is an aerospace company developing orbital transfer vehicles and space propulsion technologies, including space nuclear options, to enable flexible and cost-efficient access to space. The company's systems are designed to provide maneuverability and a sustainable orbital environment, allowing satellite operators to reach diverse orbits and destinations without relying on heavy, costly propulsion. By simplifying access to space and reducing propulsion burdens, Atomos Space seeks to lower operating costs and expand the range of viable mission profiles for payloads in orbit.

Cajal Neuroscience is a biotechnology company dedicated to discovering novel targets and therapeutics for neurodegeneration. It integrates human genetics, functional genomics, and advanced microscopy to accelerate drug discovery in this field.

Founded in 2016, MedCrypt specializes in cybersecurity software for medical devices. Its solutions ensure data security and protect against unauthorized access across a wide range of devices, from pacemakers to surgical robots.

Canaery is developing a neural interface that analyzes an object's scent fingerprint to identify dangerous compounds at ports and inspection points, potentially replacing or supplementing x-ray and camera methods. The company aims to digitize the sense of scent through a neurotech device that interprets scents entering an olfactory system and prioritizes those relevant to customers, enabling the identification of hazardous compounds and the underlying object or its state. By translating olfactory information into actionable signals, Canaery seeks to enhance security and inspection efficiency in high-risk environments.

OKAPI:Orbits provides an AI-powered space traffic management platform that predicts collision risks, manages conjunctions, and optimizes satellite operations to enable safer, more efficient use of crowded orbits. The platform includes environment visualization, maneuver design, conjunction analysis, re-entry predictions, high-accuracy orbit propagation and determination, and pass prediction, with secure ground-segment integration for space operators and institutions. The company aims to support sustainable space activity by reducing collision risk and enabling reliable operations in increasingly congested space.

Ubotica develops artificial intelligence-enabled satellite systems that analyze images onboard in real-time, autonomously adjust tasks based on insights, and deliver outputs directly to users.

DigiLens is a Sunnyvale, California-based developer of holographic waveguide display technology and photopolymer optical platforms for extended reality (XR). The company offers waveguide displays, light engines, and development kits to help OEMs design XR-enabled devices for automotive, enterprise, consumer, avionics, and defense applications. Its patented optical platform and a low-cost contact-copy manufacturing process support compact, high-fidelity XR modules, including augmented reality and heads-up display solutions. DigiLens focuses on enabling OEM partners to create customized XR experiences by combining materials, software tools, and display architectures that extend the field of view and reduce device size and weight.

Diamond Age is a company focused on automating the home construction process within the production housing industry. By leveraging advanced technologies such as 3D printing, mechatronics, and robotics, Diamond Age aims to address significant labor shortages and enhance efficiency in construction. The company's Robotics-as-a-Service system streamlines the building process, reducing construction timelines from approximately nine months to just thirty days. Additionally, Diamond Age collaborates with landholders to simplify the supply chain, enabling more affordable housing options for home buyers. Through its innovative approach, the company seeks to unlock substantial growth potential in the housing market.

Founded in 2015, Mojo Vision specializes in developing and commercializing advanced micro-LED display technology for various applications. The company is renowned for creating the world's smallest dynamic display for augmented reality smart contact lenses. Headquartered in Saratoga, California, Mojo Vision aims to disrupt the $160 billion display industry with its proprietary quantum-dot technology.

MindImmune Therapeutics is a pharmaceutical company that develops antibody-based therapies targeting the immune system to treat diseases of the central nervous system. Its programs aim to address neuroinflammation associated with brain disorders such as Alzheimer's disease, Huntington's disease, pain, and psychiatric conditions. The company emphasizes the role of immune dysfunction in CNS pathology and seeks to inhibit peripheral innate immune responses to produce therapeutic effects. Based in Kingston, Rhode Island, MindImmune pursues collaborations with neuroscience research institutions to advance its drug development initiatives.

Founded in 2015, Ursa Major Technologies specializes in manufacturing advanced propulsion solutions for microsatellite and nanosatellite launch markets. Its products include the Hadley and Ripley engines, which are over 80% additively manufactured using innovative materials and processes.

Sepion Technologies is an advanced membrane company based in Emeryville, California, founded in 2015. It specializes in the development of highly-tunable nanoscale membranes designed for various industrial applications, particularly in the energy storage sector. The company focuses on manufacturing innovative lithium-metal batteries by integrating nanoscience, polymer chemistry, and cell engineering. Its proprietary composite membrane serves as a cost-effective alternative to traditional ceramic separators used in lithium batteries, allowing for large-area production. This technology enables battery manufacturers to enhance energy density in their products, thereby improving overall performance and efficiency in energy storage solutions.

Cala Health is a bioelectronic medicine company that develops wearable neuromodulation therapies for chronic diseases. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor.

DigiLens is a Sunnyvale, California-based developer of holographic waveguide display technology and photopolymer optical platforms for extended reality (XR). The company offers waveguide displays, light engines, and development kits to help OEMs design XR-enabled devices for automotive, enterprise, consumer, avionics, and defense applications. Its patented optical platform and a low-cost contact-copy manufacturing process support compact, high-fidelity XR modules, including augmented reality and heads-up display solutions. DigiLens focuses on enabling OEM partners to create customized XR experiences by combining materials, software tools, and display architectures that extend the field of view and reduce device size and weight.

Founded in 2019, TripleBlind operates an online platform enabling entities to collaborate on sensitive data and algorithms without compromising privacy. Its software-only solution, delivered via API, focuses on healthcare and financial services, supporting various data types and cloud platforms. Backed by Accenture, General Catalyst, and Mayo Clinic, TripleBlind ensures compliance with HIPAA and GDPR.

Calicat is a clean-energy company developing a proprietary electrocatalyst discovery process for electrolyser. The company electrocatalyst discovery is an unprecedented, proprietary, end-to-end ultrahigh throughput AI and data-driven process focused on the discovery of new catalysts for the generation of clean hydrogen and fuel cell power production. The process prepares, characterizes, and quantifies the catalytic activity of millions of compositions per month and then closes the loop with big data analysis and AI to refine/guide the search.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

Diamond Age is a company focused on automating the home construction process within the production housing industry. By leveraging advanced technologies such as 3D printing, mechatronics, and robotics, Diamond Age aims to address significant labor shortages and enhance efficiency in construction. The company's Robotics-as-a-Service system streamlines the building process, reducing construction timelines from approximately nine months to just thirty days. Additionally, Diamond Age collaborates with landholders to simplify the supply chain, enabling more affordable housing options for home buyers. Through its innovative approach, the company seeks to unlock substantial growth potential in the housing market.

Paradromics, Inc. is a company focused on developing advanced brain-machine interfaces aimed at transmitting data between the brain and external devices. Founded in 2015 and based in Austin, Texas, Paradromics manufactures implantable systems that facilitate neural data decoding, converting intricate neural recordings into data streams suitable for various neural prostheses. The company's technology is designed to enhance data transmission rates, providing high-volume, bidirectional data streaming capabilities. This innovation aims to assist individuals with neurodegenerative diseases and other neurological conditions by compensating for the loss of biological connectivity. In addition to its core products, Paradromics also develops applications to support its technology solutions.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Founded in 2019, TripleBlind operates an online platform enabling entities to collaborate on sensitive data and algorithms without compromising privacy. Its software-only solution, delivered via API, focuses on healthcare and financial services, supporting various data types and cloud platforms. Backed by Accenture, General Catalyst, and Mayo Clinic, TripleBlind ensures compliance with HIPAA and GDPR.

Roviero develops native graph processors for edge computing, aiming to democratize AI compute. Their CortiOne™ NPE and CortiSoft™ compiler technology enable unrivaled performance with minimal power consumption and latency on edge devices like cameras, IoT devices, mobile phones, and computers.

CytoVale is a medical technology company based in San Francisco that develops biomarkers derived from the mechanical properties of single cells. The company uses microfluidics to route and probe cells, enabling the measurement of multiple biophysical indicators at once. Its technology aims to advance early detection of immune-mediated diseases and sepsis through the analysis of cell mechanics and machine learning. By translating biophysical signals into diagnostic information, CytoVale seeks to improve diagnostic accuracy, support timely treatment decisions, and reduce healthcare costs.

Sea Machines Robotics, headquartered in Boston, Massachusetts, specializes in developing and manufacturing advanced autonomous control and navigation systems for the commercial marine industry. Established in 2014, the company produces systems like SM300 for remote vessel command, SM200 for collaborative operations, SM400 for AI-powered situational awareness on container ships, RC NXT for PLC-based wireless control, and DP-NXT for crew reduction or elimination on vessels. Sea Machines offers solutions for various unmanned applications, including bathymetric surveys, AUV-tendering, subsea asset inspection, passive acoustic monitoring, and dual towing.

Authentic Vision GmbH is a company specializing in anti-counterfeiting and authentication technologies aimed at safeguarding investments in product innovation, brand value, and reputation. Founded in 2012 and headquartered in Salzburg, Austria, with an additional office in Saratoga, California, the company offers a unique solution that includes a patented label technology combining QR code features with holographic security aspects. Its flagship product, the CheckifReal application, allows users to visually distinguish between authentic and counterfeit labels. Additionally, Authentic Vision provides services for customer communication, client label management, and business intelligence. The company holds multiple patents and collaborates closely with universities and leading security printing firms to remain at the forefront of advancements in brand protection and consumer engagement solutions.

Libra Therapeutics is a biotechnology company dedicated to developing novel disease-modifying therapeutics for neurodegenerative diseases. Its platform focuses on restoring cellular balance through small molecule drugs that attenuate the production of neurotoxic proteins, targeting conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

NativeWaves is a technology company that specializes in audio synchronization and streaming solutions aimed at enhancing live event viewing experiences. By collaborating with partners, the company identifies compelling content and develops tools that allow for personalized and synchronized delivery of multimedia content across multiple screens. NativeWaves' software effectively translates movies, sports events, and videos into various languages without causing interruptions or synchronization delays. Additionally, it provides real-time statistics and insights on alternate screens, enabling viewers to engage with their favorite events in preferred languages and formats. The company's commitment to delivering intuitive and user-friendly technology ensures that existing workflows remain unchanged while enhancing the overall experience for audiences worldwide.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.

Atmosic Technologies is a fabless semiconductor company that designs ultra-low power wireless technologies to dramatically extend battery life or enable battery-free IoT devices by harvesting ambient energy such as light, radio frequency, thermal, and kinetic sources. Its solutions power devices in wearables, remotes, beacons, sensors, and asset trackers, helping designers and manufacturers reduce maintenance costs for connected IoT deployments across personal, home, auto, healthcare, industrial, and enterprise settings. The ATM2, ATM3, ATM33, and ATM34 series support multiple IoT applications. The company was founded in 2016 and is based in Campbell, California.

GenomSys develops a robust, interoperable platform for efficient processing, sharing, and analysis of genomic data. Its solutions enable secure storage of individual DNA on personal devices and sharing with practitioners for diagnostics, pharmacogenomics, personalized treatments, and other applications using genetic data to improve quality of life.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Lightform, Inc. is a computer vision and hardware company based in San Francisco, California, founded in 2014. The company specializes in developing technology for projected augmented reality, offering sound-reactive projectors, projector kits, and creator products that transform spaces through projection mapping. Lightform's innovative hardware tools and desktop application enable users to create animated content for various scenes, control projectors wirelessly from laptops or phones, and seamlessly integrate real objects with projected light. The company also provides 3D scanning options that allow for the scanning of complex scenes, automatically fine-tuning alignment and enhancing the projection mapping workflow with AI-generated effects and filters.

NativeWaves is a technology company that specializes in audio synchronization and streaming solutions aimed at enhancing live event viewing experiences. By collaborating with partners, the company identifies compelling content and develops tools that allow for personalized and synchronized delivery of multimedia content across multiple screens. NativeWaves' software effectively translates movies, sports events, and videos into various languages without causing interruptions or synchronization delays. Additionally, it provides real-time statistics and insights on alternate screens, enabling viewers to engage with their favorite events in preferred languages and formats. The company's commitment to delivering intuitive and user-friendly technology ensures that existing workflows remain unchanged while enhancing the overall experience for audiences worldwide.

Kuprion Inc., established in 2016 and headquartered in Palo Alto, California, specializes in manufacturing and licensing nano copper inks and pastes. The company's flagship product, NSA-16, is a nano copper solder adhesive designed for assembly in printable and flexible electronics, cables, displays, touch screens, antennas, RFID tags, additive manufacturing, injection molding, and antimicrobial applications in healthcare. Kuprion serves diverse markets such as aerospace, automotive, printed electronics, consumer electronics, mining, oil and gas, manufacturing, and laser diodes. The company's revolutionary nanoCopper technology, originally researched at Lockheed Martin, offers superior electrical and thermal conductivity, enabling smaller, more powerful products. Since commercializing the technology in 2019, Kuprion has secured Fortune 100 customers, obtained over 20 patents, and established offices and manufacturing facilities in San Jose, California.

Phylagen is a data analytics company that leverages artificial intelligence to analyze the microbiome. It uses DNA sequencing and machine learning to derive insights from this vast, unseen world of microbes, benefiting customers across various industries.

Ultraleap specializes in developing and commercializing innovative haptic control systems. Founded in 2013, the company is renowned for its mid-air haptics and 3D hand tracking technologies. Ultraleap's solutions include Leap Motion Controller for optical hand tracking, VR Developer Mount for virtual reality experiences, and Gemini, a hand tracking platform. Its applications span across extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment.

Founded in 2015, Mojo Vision specializes in developing and commercializing advanced micro-LED display technology for various applications. The company is renowned for creating the world's smallest dynamic display for augmented reality smart contact lenses. Headquartered in Saratoga, California, Mojo Vision aims to disrupt the $160 billion display industry with its proprietary quantum-dot technology.

System1 Biosciences, Inc. is a San Francisco-based neurotherapeutics company established in 2017, specializing in drug discovery for complex neurological and psychiatric disorders, including epilepsy, autism, and schizophrenia. The company employs phenotypic screening, integrating cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to uncover novel characterizations of diseases. This innovative approach allows System1 to identify "deep phenotypes," which are utilized to discover new therapeutic targets and drug treatments, addressing gaps in traditional discovery techniques that have struggled with these challenging conditions.

Vium, Inc. is a biotechnology company founded in 2013 and headquartered in San Mateo, California. It specializes in developing digital biomarkers aimed at enhancing preclinical research and animal welfare. The company is fully accredited by AAALAC International and has received significant commendation for its commitment to the principles of humane animal research. Vium's digital platform, known as Digital Vivarium and Vium Cloud, utilizes advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively collect physiological metrics and behaviors. This innovative approach enables researchers and drug developers to gain improved insights into disease progression, thereby facilitating better decision-making regarding which compounds should progress to clinical trials. Its clientele includes a diverse array of biotechnology, pharmaceutical, and academic institutions, as well as novel therapeutic laboratories, all seeking more sensitive and accurate data for replicable studies.

Paradromics, Inc. is a company focused on developing advanced brain-machine interfaces aimed at transmitting data between the brain and external devices. Founded in 2015 and based in Austin, Texas, Paradromics manufactures implantable systems that facilitate neural data decoding, converting intricate neural recordings into data streams suitable for various neural prostheses. The company's technology is designed to enhance data transmission rates, providing high-volume, bidirectional data streaming capabilities. This innovation aims to assist individuals with neurodegenerative diseases and other neurological conditions by compensating for the loss of biological connectivity. In addition to its core products, Paradromics also develops applications to support its technology solutions.

Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.

Quince Therapeutics is a preclinical-stage biopharmaceutical company focused on developing precision therapeutics for debilitating and rare diseases. Its core technology is a bone-targeting drug platform designed to deliver small molecules, peptides, or large molecules directly to the site of bone fractures and diseases, promoting rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Founded in 2015, Phase Four specializes in developing electric propulsion systems for small satellites. Its signature product is the Radio Frequency Thruster (RFT), which offers significant cost savings, reduced size, and propellant flexibility while maintaining high performance. The company's solutions enable clients to maneuver satellites into various orbits economically.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

Envisagenics is a Huntington, New York-based company that develops a predictive analytics and bioinformatics platform to accelerate RNA therapeutics discovery. The cloud-based SpliceCore platform analyzes RNA sequencing data with artificial intelligence to identify splicing errors linked to disease, predict drug targets, and guide the design of RNA-based therapies. By translating transcriptomic insights into actionable targets, Envisagenics aims to reduce the time, cost, and risk of pharmaceutical development and to support partnerships with biopharma organizations. The firm focuses on uncovering RNA splicing alterations and translating them into therapeutic candidates, enabling researchers to validate targets and biomarkers more efficiently. The company originated as a spinout from Cold Spring Harbor Laboratory and emphasizes the use of AI and machine learning to simplify complex biomedical data for therapeutic discovery.

Founded in 2015, Ursa Major Technologies specializes in manufacturing advanced propulsion solutions for microsatellite and nanosatellite launch markets. Its products include the Hadley and Ripley engines, which are over 80% additively manufactured using innovative materials and processes.

Lightform, Inc. is a computer vision and hardware company based in San Francisco, California, founded in 2014. The company specializes in developing technology for projected augmented reality, offering sound-reactive projectors, projector kits, and creator products that transform spaces through projection mapping. Lightform's innovative hardware tools and desktop application enable users to create animated content for various scenes, control projectors wirelessly from laptops or phones, and seamlessly integrate real objects with projected light. The company also provides 3D scanning options that allow for the scanning of complex scenes, automatically fine-tuning alignment and enhancing the projection mapping workflow with AI-generated effects and filters.

Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.

Stellar Labs, Inc., incorporated in 2014 and based in Burlingame, California, operates within the technology sector, focusing on the private aviation industry. The company has developed an advanced commercial operations system that integrates an all-digital distribution network, aiming to transform and enhance business aviation. Stellar Labs offers a suite of cloud-based applications designed to cater to a range of operational needs, from simple single-aircraft management to complex operations involving large fleets and multiple bases. This innovative approach positions Stellar Labs as a key player in revolutionizing the efficiency and effectiveness of private aviation services.

Chirp Microsystems, Inc. is a company specializing in the design, development, and manufacturing of low power ultrasonic three-dimensional sensing solutions. Founded in 2013 and headquartered in Berkeley, California, the company focuses on applications in consumer electronics, smart homes, and industrial automation. Chirp's systems deliver millimeter-accurate range information, utilizing machine learning and neural network algorithms to outperform traditional infrared-based alternatives in various real-world scenarios. Their innovative technology enables always-on sensing capabilities for smart home devices, even when operating on battery power, thus enhancing functionality and user experience across their target markets.

Founded in 2009, Mixed Dimensions specializes in developing software solutions that bridge the digital and physical worlds. The company offers services such as Makeprintable, a cloud-based platform for optimizing 3D CAD files; 3D Collectible, a service combining printing technology with market printers; and Gameprint, a platform enabling users to capture and print 3D gameplay moments.

Alzeca Biosciences, founded in 2011 and headquartered in Houston, Texas, specializes in developing novel magnetic resonance imaging (MRI) contrast agents for early diagnosis of neurodegenerative diseases like Alzheimer's. Its flagship product, ADx nanoparticle, targets amyloid plaques, currently undergoing Phase 1 human clinical trials. The company aims to address the growing global prevalence and economic burden of Alzheimer's disease, which affects millions worldwide and is projected to quadruple by 2050 without more effective diagnostic methods.

Tempo Automation Holdings, established in 2013 and headquartered in San Francisco, specializes in manufacturing low-volume electronics products. The company's core business involves designing and assembling printed circuit boards (PCBs) using a unique, software-automated platform. This platform enables Tempo to provide unparalleled speed, quality, and transparency, particularly during the critical prototype and new product introduction stages. Serving leading innovators across industries such as aerospace, medical technology, and automotive, Tempo Automation empowers its customers to accelerate product development and time to market.

Ultraleap specializes in developing and commercializing innovative haptic control systems. Founded in 2013, the company is renowned for its mid-air haptics and 3D hand tracking technologies. Ultraleap's solutions include Leap Motion Controller for optical hand tracking, VR Developer Mount for virtual reality experiences, and Gemini, a hand tracking platform. Its applications span across extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment.

Quince Therapeutics is a preclinical-stage biopharmaceutical company focused on developing precision therapeutics for debilitating and rare diseases. Its core technology is a bone-targeting drug platform designed to deliver small molecules, peptides, or large molecules directly to the site of bone fractures and diseases, promoting rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.

Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.

DigiLens is a Sunnyvale, California-based developer of holographic waveguide display technology and photopolymer optical platforms for extended reality (XR). The company offers waveguide displays, light engines, and development kits to help OEMs design XR-enabled devices for automotive, enterprise, consumer, avionics, and defense applications. Its patented optical platform and a low-cost contact-copy manufacturing process support compact, high-fidelity XR modules, including augmented reality and heads-up display solutions. DigiLens focuses on enabling OEM partners to create customized XR experiences by combining materials, software tools, and display architectures that extend the field of view and reduce device size and weight.

Tetra Therapeutics Inc. is a clinical-stage biotechnology company focused on developing pharmaceutical drugs that target phosphodiesterase (PDE) subtype inhibitors for various neurological and non-neurological disorders. The company is advancing BPN14770, a novel therapeutic agent designed to enhance synaptic actions in the brain's neurons, which is particularly relevant for conditions affecting memory and cognition, such as Alzheimer's disease, schizophrenia, and developmental disabilities. Tetra Therapeutics aims to create effective treatments for patients suffering from Alzheimer's, other dementias, traumatic brain injury, and psychiatric disorders. Founded in 2011 and based in Grand Rapids, Michigan, the company was previously known as Tetra Discovery Partners and rebranded in August 2019. Tetra Therapeutics has established a strategic collaboration with Shionogi & Co., Ltd., and as of July 2020, operates as a subsidiary of Shionogi.

Podium Data, Inc. is a data management software company based in Lowell, Massachusetts, founded in 2014. It specializes in providing an enterprise data management platform that transforms traditional data supply chains into a self-service, on-demand marketplace. This platform allows businesses to efficiently manage, prepare, and deliver analytics-ready data to users across various data landscapes. Podium Data's solutions include capabilities for source parsing, data profiling, metadata management, data integration, and data transformation, among others. By leveraging big data technologies, the company aims to accelerate the time-to-answer for businesses, enabling them to quickly find, understand, and utilize any enterprise data source, regardless of its physical location. As of 2018, Podium Data operates as a subsidiary of Qlik Technologies, Inc.

3Scan develops robotic microscopy tools and software for large-scale tissue analysis and three-dimensional visualization. It builds devices that automate tissue sectioning and integrates automation with machine learning and computer vision to extract spatial data from tissue and generate detailed three-dimensional representations and quantitative analyses of complex anatomical structures. These capabilities enable higher-throughput histology and broader image analysis for researchers and clinicians, supporting advances in diagnostics and therapeutics for diseases such as cancer, neurodegenerative conditions, and cardiovascular disease.

Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.

Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.

Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.

Modsy is a home design company that leverages advanced 3D graphics and computer vision technology to offer personalized interior design solutions. Founded in 2015 and based in San Francisco, the company enables customers, including new homeowners, remodelers, and renters, to visualize inspirational designs and decor within their own spaces before making any changes. Modsy's software allows users to see how furniture and decor will look in their homes, providing tailored room layouts and recommendations. It also features a shoppable marketplace, allowing customers to purchase items directly from their design plans, thereby simplifying the home design process and eliminating guesswork for both home renovators and interior designers.

Quince Therapeutics is a preclinical-stage biopharmaceutical company focused on developing precision therapeutics for debilitating and rare diseases. Its core technology is a bone-targeting drug platform designed to deliver small molecules, peptides, or large molecules directly to the site of bone fractures and diseases, promoting rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Eargo, Inc. is a consumer-focused medical device company specializing in the design and sale of hearing aids for individuals with hearing loss in the United States. Founded in 2010 and headquartered in San Jose, California, Eargo offers innovative, rechargeable hearing aids that can be controlled via smartphone, enhancing user convenience. The company provides online hearing screenings and virtual support, eliminating the need for in-person consultations. By adopting a direct-to-consumer model, Eargo aims to make hearing aids more accessible and reduce the social stigma often associated with them. Its user-centric approach addresses the common challenges of traditional hearing aid adoption, including cost and accessibility, thereby improving the quality of life for those with hearing difficulties.

PharmatrophiX, Inc. is a biopharmaceutical company based in Menlo Park, California, specializing in the development of disease-modifying small molecule drugs for neurodegenerative disorders. Founded in 2005 by Stanford researcher Frank Longo, the company focuses on creating drugs that mimic the activity of neurotrophins, proteins crucial for the health and survival of neurons. PharmatrophiX utilizes its proprietary technology to develop small molecules that modulate neurotrophin receptor signaling, particularly targeting the p75 receptor and Trk ligand programs. One of its notable compounds, a modified version of LM11A-31, can penetrate the blood-brain barrier, making it essential for treating brain disorders. The company's innovations aim to decrease synaptic and neuronal degeneration, offering potential treatments for conditions such as Alzheimer's disease.